Document Detail


Brain activity in adolescent major depressive disorder before and after fluoxetine treatment.
MedLine Citation:
PMID:  22267183     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Major depression in adolescents is a significant public health concern because of its frequency and severity. To examine the neurobiological basis of depression in this population, the authors studied functional activation characteristics of the brain before and after antidepressant treatment in antidepressant-naive depressed adolescents and healthy comparison subjects.
METHOD: Depressed (N=19) and healthy (N=21) adolescents, ages 11 to 18 years, underwent functional MRI assessment while viewing fearful and neutral facial expressions at baseline and again 8 weeks later. The depressed adolescents received 8 weeks of open-label fluoxetine treatment after their baseline scan.
RESULTS: Voxel-wise whole brain analyses showed that depressed youths have exaggerated brain activation compared with healthy comparison subjects in multiple regions, including the frontal, temporal, and limbic cortices. The 8 weeks of fluoxetine treatment normalized most of these regions of hyperactivity in the depressed group. Region-of-interest analyses of the areas involved in emotion processing indicated that before treatment, depressed youths had significantly greater activations to fearful relative to neutral facial expressions than did healthy comparison subjects in the amygdala, orbitofrontal cortex, and subgenual anterior cingulate cortex bilaterally. Fluoxetine treatment decreased activations in all three regions, as compared with the repeat scans of healthy comparison subjects.
CONCLUSIONS: While effective treatments are available, the impact of depression and its treatment on the brain in adolescents is understudied. This study confirms increases in brain activation in untreated depressed adolescents and demonstrates reductions in these aberrant activations with treatment.
Authors:
Rongrong Tao; Clifford S Calley; John Hart; Taryn L Mayes; Paul A Nakonezny; Hanzhang Lu; Betsy D Kennard; Carol A Tamminga; Graham J Emslie
Related Documents :
24357823 - Facemask therapy between ages six to ten years may lead to short term improvements for ...
23850163 - Quality of life in patients with ileal conduit cystectomy due to bladder cancer.
25117163 - Isotretinoin and night blindness.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of psychiatry     Volume:  169     ISSN:  1535-7228     ISO Abbreviation:  Am J Psychiatry     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-10     Completed Date:  2012-06-12     Revised Date:  2014-11-10    
Medline Journal Info:
Nlm Unique ID:  0370512     Medline TA:  Am J Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  381-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adolescent Behavior / drug effects*,  physiology*
Brain / drug effects,  physiopathology*
Child
Depressive Disorder, Major / drug therapy*,  physiopathology*
Facial Expression
Female
Fluoxetine / pharmacology,  therapeutic use*
Functional Neuroimaging / methods,  psychology
Humans
Magnetic Resonance Imaging / methods,  psychology*
Male
Photic Stimulation / methods
Grant Support
ID/Acronym/Agency:
P50 MH096890/MH/NIMH NIH HHS; R01 MH084021/MH/NIMH NIH HHS; R01 MH39188/MH/NIMH NIH HHS; R34 MH072737/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
01K63SUP8D/Fluoxetine
Comments/Corrections
Comment In:
Am J Psychiatry. 2012 Apr;169(4):348-50   [PMID:  22476672 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Borromean-Entanglement-Driven Assembly of Porous Molecular Architectures with Anion-Modified Pore Sp...
Next Document:  Increased medial orbitofrontal and amygdala activation: evidence for a systems-level endophenotype o...